Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens Journal Article
| Authors: | Kumar, S.; Giralt, S.; Stadtmauer, E. A.; Harousseau, J. L.; Palumbo, A.; Bensinger, W.; Comenzo, R. L.; Lentzsch, S.; Munshi, N.; Niesvizky, R.; Miguel, J. S.; Ludwig, H.; Bergsagel, L.; Blade, J.; Lonial, S.; Anderson, K. C.; Tosi, P.; Sonneveld, P.; Sezer, O.; Vesole, D.; Cavo, M.; Einsele, H.; Richardson, P. G.; Durie, B. G. M.; Rajkumar, S. V. |
| Article Title: | Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens |
| Abstract: | The past decade has witnessed a paradigm shift in the initial treatment of multiple myeloma with the introduction of novel agents such as thalidomide, lenalidomide, and bortezomib, leading to improved outcomes. High-dose therapy and autologous stem cell transplantation remains an important therapeutic option for patients with multiple myeloma eligible for the procedure. Before the advent of the novel agents, patients underwent stem cell collection prior to significant alkylating agent exposure, given its potential deleterious effect on stem cell collection. With increasing use of the novel agents in the upfront setting, several reports have emerged raising concerns about their impact on the ability to collect stem cells.An expert panel of the International Myeloma Working Group (IMWG) was convened to examine the implications of these therapies on stem collection in patients with myeloma and to develop recommendations for addressing these issues. Here we summarize the currently available data and present our perspective on the problem and potential options to overcome this problem. Specifically, we recommend early mobilization of stem cells, preferably within the first 4 cycles of initial therapy, in patients treated with novel agents and encourage participation in clinical trials evaluating novel approaches to stem cell mobilization. © 2009 by The American Society of Hematology. |
| Keywords: | controlled study; lenalidomide; thalidomide; clinical trial; review; doxorubicin; multimodality cancer therapy; antineoplastic agents; clinical trials as topic; combined modality therapy; methodology; antineoplastic agent; bortezomib; multiple myeloma; boronic acids; pyrazines; bone marrow suppression; blood toxicity; cyclophosphamide; dexamethasone; vincristine; hematopoietic stem cell transplantation; drug effect; oncology; stem cell; stem cell mobilization; drug derivative; medical oncology; consensus development; alkylation; granulocyte colony stimulating factor; boronic acid derivative; pyrazine derivative; cell motility; hematopoietic stem cell mobilization; immunosuppressive agents; immunosuppressive agent; cell transplantation; myeloma; consensus development conferences as topic |
| Journal Title: | Blood |
| Volume: | 114 |
| Issue: | 9 |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2009-01-01 |
| Start Page: | 1729 |
| End Page: | 1735 |
| Language: | English |
| DOI: | 10.1182/blood-2009-04-205013 |
| PUBMED: | 19561323 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 16" - "Export Date: 30 November 2010" - "CODEN: BLOOA" - "Source: Scopus" |
